Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Khalighfard, Solmaza; b | Kalhori, Mohammad Rezac | Amiriani, Taghid | Poorkhani, Amirhoushangd | Khori, Vahidd | Esmati, Ebrahima | Lashkari, Marzieha | Najafi, Alie; 1 | Alizadeh, Ali Mohammadb; f; 1; *
Affiliations: [a] Radiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran | [b] Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran | [c] Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran | [d] Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran | [e] Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran | [f] Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
Correspondence: [*] Corresponding author: Ali Mohammad Alizadeh, Cancer Research Center, Tehran University of Medical Sciences, Tehran, P.O. 1419733141, Iran. Tel./Fax: +98 21 6119 2501; E-mail: aalizadeh@sina.tums.ac.ir.
Note: [1] Ali Najafi and Ali Mohammad Alizadeh contributed equally to this work.
Abstract: BACKGROUND: The discovery of miRNA/mRNA interactions in several biological samples prompted the researchers to explore new biomarkers in tumors. OBJECTIVE: We aimed to investigate the interactions of miRNA/mRNA in response to radiotherapy in the plasma samples of rectal cancer patients. METHODS: Five microarray datasets related to cancerous and non-cancerous individuals were first used to construct networks. The databases of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied to analyze pathway enrichment. The plasma samples were then collected from 55 patients with recently diagnosed rectal cancer and 10 healthy subjects. For radiotherapy courses, the patients have consecutively received 30 sessions of local radiation for six weeks. At last, the expression of selected genes and miRNAs was experimentally measured before and after radiotherapy by qPCR, and the protein levels of the target genes were measured by ELISA assay. We evaluated the therapeutic responses based on the tumor regression grade of the Dworak classification. RESULTS: We identified 5 up-regulated and 5 down-regulated miRNAs and 8 up-regulated and 3 down-regulated genes of the databases. There was a significant increase in tumor suppressor miRNAs, including miR-101-3p, miR-145-5p, miR-26a-5p, miR-34a-5p, and a significant decrease in oncomiRs, including miR-221-3p and miR-17-5p, after radiotherapy compared to the pre-treatment. Moreover, the up-regulated miR-17-5p and miR-221-5p and the down-regulated miR-101-3p and miR-145-5p were directly related to rectal cancer through the interaction with the Wnt, RAS, PI3K, and TGF-β signaling pathways. An analysis of receiver operating characteristics showed that miRNAs 221, 17, and 23 were response-related in locally advanced rectal cancer patients. CONCLUSIONS: It seems that monitoring the miRNA/mRNA interactions during radiotherapy can be an appropriate diagnostic tool to track the recovery process and respond to standard therapies.
Keywords: Radiotherapy, rectal cancer, gene, protein, microarray, microRNA
DOI: 10.3233/CBM-210079
Journal: Cancer Biomarkers, vol. 33, no. 1, pp. 97-110, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl